Review Article

The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer

Kimberly A. Placzkowski,1 Honey V. Reddi,1 Stefan K. G. Grebe,2 Norman L. Eberhardt,1,3 and Bryan McIver1

1 Division of Endocrinology, Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USA
2 Department of Laboratory Medicine and Pathology, Mayo Clinic & Foundation, Rochester, MN 55905, USA
3 Department of Biochemistry and Molecular Biology, Mayo Clinic & Foundation, Rochester, MN 55905, USA

Correspondence should be addressed to Norman L. Eberhardt, eberhardt@mayo.edu

Received 30 July 2008; Accepted 9 September 2008

Recommended by Dipak Panigrahy

Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPARγ translocation in follicular thyroid carcinoma has promoted progress in the role of PPARγ as a tumor suppressor and potential therapeutic target. The PAX8/PPARγ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPARγ, and stimulates transcription of PAX8-responsive promoters. PPARγ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.

Copyright © 2008 Kimberly A. Placzkowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Thyroid cancer is the most frequent endocrine malignancy. While relatively uncommon, the American Cancer Society estimates that there will be over 37,000 new cases in 2008 in the United States [1]. The majority of thyroid cancers are well-differentiated malignancies originating from the thyroid follicular cells. Papillary thyroid carcinomas (PTCs) are the most frequent histotype, particularly in iodine-sufficient areas, while follicular thyroid carcinoma (FTC) and Hürthle cell carcinomas (HCCs) together represent around 20% of thyroid cancer. However, these latter thyroid cancer types are often more aggressive, more advanced at the time of diagnosis, less responsive to traditional therapy, and more likely to cause both morbidity and mortality. FTC share similar cytologic features with follicular adenomas (FAs) and are distinguished only by the presence of invasion beyond the tumor capsule or into blood vessels on pathology. This common histology suggests an adenoma to carcinoma sequence, with adenomas representing a premalignant lesion, though this remains unproven.

However, the peroxisome proliferator-activated receptors (PPARs), including α, β, δ, and γ subtypes, are part of the ubiquitous nuclear hormone receptor superfamily that has been the focus of considerable research over the last two decades. PPARγ is best known in the endocrine world for its role in adipogenesis and insulin sensitization. However, it also plays a role in cell cycle control, inflammation, atherosclerosis, apoptosis, and carcinogenesis through its influence on gene expression involving multiple cell signaling pathways [2]. Research on PPARγ as a potential thyroid proto-oncogene was accelerated by the discovery of a chromosomal translocation involving the PPARγ-1 gene in a subset of follicular carcinomas [3]. Since that time, considerable effort has gone into further clarifying the possible effect of PPARγ in several cancers, including FTC.
2. **PPARγ AND THYROID CANCER**

Chromosome analysis and microsatellite mapping techniques have revealed a number of chromosomal changes associated with thyroid carcinogenesis, and pointed to specific loci that might harbor oncogenes or tumor suppressor genes, including a region spanning the fragile site on chromosome 3p14, through 3pter that is often disrupted in follicular thyroid cancers [4]. Jenkins et al. had already described a somatic mutation involving 3p25-p21 region in three cases of follicular thyroid cancer [5, 6], and there followed a number of reports of balanced translocations or aneusomy involving this chromosomal region in FTC, HCC, PTC, and anaplastic thyroid cancers (ATCs) [7–11].

A specific translocation, t(2;3)(q13;p25), was described in a case of aggressive FTC associated with bone metastases [11], though it was also seen in some FAs [10]. The importance of this chromosomal rearrangement and the mechanism of its oncogenic activity remained unclear until Kroll et al. mapped the involved 3p25 locus in a number of FTC to the PPARγ gene in 2000 [3]. Thus these data were the first to convincingly link the PPARγ gene to thyroid cancer. Altered PPARγ activity has subsequently been shown to have a potential role in several types of thyroid cancer.

Several reports of ATC, FTC, and some PTC cell lines have demonstrated PPARγ mRNA expression by reverse-transcription polymerase chain reaction (RT-PCR), without identifiable PPARγ mutations or translocations [12–15]. In these PPARγ-positive cell lines, PPARγ ligands (troglitazone [15, 16], ciglitazone [12, 14, 17], rosiglitazone [12], prostaglandin J2 [13, 15, 17], and RS1303 [13]) inhibit growth of cells, while no change in growth is seen in PPARγ-negative cell lines. Growth suppression was dose-dependent [13, 16, 17], and one study found a correlation between PPARγ expression and response to PPARγ ligands [13], though another did not [16]. Levels of Bax protein and c-myc, both apoptosis-related proteins, were increased in a dose-dependent fashion by treatment with PPARγ ligand [13, 15], although one study found increased levels of a different apoptotic protein, Bcl-2, rather than of Bax [12].

Inhibition of cell invasion [13], attachment [12, 17], and anchorage-independent growth on soft agar [12], all features of malignancy, are also seen with PPARγ ligand treatment in thyroid cancer cell lines. Finally, evidence of cell death, with decreased viable cell numbers and increased rates of necrosis and apoptosis, has been reported by some groups following PPARγ agonist treatment [12, 17]. This reduction in cell viability may be inhibited by coinoculation with GW6966, a selective PPARγ antagonist, suggesting that the described changes in cell growth and survival were truly PPARγ-dependent [12].

Addition of PPARγ agonist to PPARγ-positive cells lines led to an increased portion of cells in G0/G1 with a reduction of cells in G2/M and S phase, consistent with decreased cell proliferation [12]. DNA synthesis appeared to be slowed with decreased 3H-thymidine incorporation in these cells, while expression of the cell-cycle progression inhibitors p21cip1 and p27kip1 were increased [12]. Overexpression of the PPARγ gene by transfection into PPARγ-positive or -negative cell lines similarly decreased colony formation and triggered nuclear condensation, fragmentation of chromatin and apoptosis, with G0/G1 cell cycle arrest [12, 14–16]. Together, these data provide strong support that PPARγ has a tumor suppressive effect in thyroid follicular cells, which is consistent with results in other nontumor thyroid cell lines [18–23].

One of the few available animal models of follicular thyroid carcinoma was created by generating homozygous mutations in the thyroid receptor gene TRβ, a mutation initially described in a patient with thyroid hormone resistance syndrome [24] and referred to as the PV/PV mutant. Homozygous TRβPV/PV mice develop follicular thyroid cancer with predictable progression from thyroid hyperplasia to capsular and vascular invasion, more extensive soft tissue invasion and ultimately lung metastasis at an early age [25]. Analysis of gene activity by cDNA microarray analysis in TRβPV/PV mice demonstrates altered regulation of several genes compared to wild-type siblings. Many of these genes are implicated in tumor-formation, metastasis, invasion, cell cycle control and apoptosis. PPARγ-mediated pathways, however, are downregulated in these mice, hinting at a role for PPARγ inhibition in this thyroid cancer model [26].

Early in the histologic progression of thyroid disease in this TRβPV/PV mouse model expression of PPARγ mRNA, assessed by Northern blot analysis, was diminished approximately 50% compared to wild-type siblings. Furthermore, not only was PPARγ activity suppressed, but the mRNA activity in mutant mice did not increase with age as was seen in their wild-type counterparts [27]. Data from humans has also implicated a functional downregulation of PPARγ expression in human thyroid tumors that did not carry PPARγ translocations, in studies using semiquantitative PCR, real-time RT-PCR, and microarray analyses [28, 29]. Furthermore, tumors with reduced PPARγ expression showed an increased incidence of distant metastases, local invasion, and areas of poor differentiation [28]. These findings suggest that downregulation of wild-type PPARγ may be a key event in thyroid carcinogenesis.

Homozygous PPARγ+/− mice, incorporating a loss of function mutation in one allele of the PPARγ gene, have been used as an animal model to evaluate the molecular genetic events ultimately leading to carcinogenesis in colon, breast, and ovarian tumors [30, 31]. Deletion of both alleles of the PPARγ gene, however, is universally lethal to embryos. In thyroid cancer, the TRβPV/PV mouse model was used to further elucidate the mechanism of PPARγ tumorigenesis. TRβPV/PV mice were crossed with PPARγ+/− mice to obtain TRβPV/PV PPARγ+/− offspring. In these mice, PPARγ mRNA and lipoprotein lipase (LpL) expression were reduced compared to wild-type mice. LpL is a downstream target gene for PPARγ, thereby confirming diminished PPARγ action. Furthermore, LpL mRNA and protein expression were further reduced in the mutant TRβPV/PV PPARγ+/− mice compared to both wild-type and TRβ+/+PPARγ+/− mice [32].

Western blot analysis demonstrated activation of the NFκB pathway in these TRβPV/PV PPARγ+/− mice [32], which is consistent with data in the PPARγ−/− mouse model [33]. Expression of cyclin D1, a cell cycle regulator important in the progression from G1 to S phase and a downstream target
of NFkB, was significantly increased. Also, cell cycle analysis in TRPV/PVPPARγ+/- mice showed a shortened G0/G1 phase and decreased apoptosis compared to TRPV/PVPPARγ+/- mice [32]. Cyclin D1 is known to be overexpressed in human thyroid carcinomas [34] and in vitro addition of a PPARγ agonist to human ATC cell lines suppresses cyclin D1 levels [12], confirming that this effect is related to alterations in PPARγ rather than TRβ. Caspase-3, a gene critical in the apoptotic signal cascade, was significantly reduced in TRPV/PVPPARγ+/- mice, a finding consistent with previous data on the downstream effects of NFkB activation in prostate cancer cells [35]. Conversely, increased levels of caspase-3 activation were seen in vitro with PPARγ agonist therapy of FTC [17] and ATC cell lines [12]. Importantly, rosiglitazone therapy slowed tumor growth and reduced capsular invasion in TRPV/PV mice, suggesting that activation of the PPARγ pathway delays disease progression [32].

In summary, several lines of evidence, in human tumors, cell lines, and animal models strongly support the hypothesis that PPARγ inhibition, downregulation, or insufficiency appears to be tumorigenic in the thyroid. This appears to be mediated through PPARγ effects on cell cycle progression and inhibition of apoptosis, thereby contributing to tumor development or progression.

3. **PAX8/PPARγ GENE TRANSLOCATION AND THYROID CANCER**

Following the identification of a frequent translocation in follicular thyroid cancer, involving 3p25 and 2q13, Kroll confirmed not only that the 3p25 breakpoint lies within the PPARγ gene, but also that the 2q13 breakpoint lies within the PAX8 gene. Indeed, the translocation brings together these two genes to form a neogene, which expresses a fusion protein (PAX8/PPARγ fusion protein, designated PPFP) [3].

Native PAX8 is a transcription factor important in thyroid follicular cell differentiation and in the regulation of a number of thyroid-specific genes [36]. The chromosomal translocation described by Kroll fuses the promoter and proximal 5’ coding sequence of PAX8 inframe with a nearly full-length PPARγ, resulting in the production of the fusion protein PPFP, whose expression is under the transcriptional regulation of the PAX8 promoter [3]. Several splice variants have been identified for PPFP, which appear to be frequently coexpressed [3, 36, 37]. Variants described to date are shown in Figure 1. In each case these PAX8 fragments are fused to PPARγ exons 1 to 6 [3, 36, 37]. All of the known variants include the paired and partial homeobox DNA binding domains of PAX8, as well as the DNA binding, ligand binding, RXR dimerization and transactivation domains of PPARγ-1 [3]. These attributes make it likely that PPFP will retain at least some of the DNA and ligand binding properties of each of the native transcription factors, with the potential for significant impact on either the PAX8- or PPARγ-mediated pathways, or both.

A number of studies, using RT-PCR, nested PCR, FISH, or Western analysis, have confirmed the relatively high prevalence of the PAX8/PPARγ rearrangement or expression of PPFP in follicular thyroid lesions, though the precise incidence varies by cell type and method of detection (Table 1). FTCs have the highest incidence at 36% (range 0–63%) with FAs exhibiting lower rates of around 11% (range 0–55%). Only one case of HCC has shown the PAX8/PPARγ rearrangement. PPFP does not appear to be expressed in classical PTC, but karyotyping has shown at (2;3)(q13;p25)
Table 1: Occurrence of PAX8/PPARγ rearrangements in differentiated thyroid carcinomas.

| Author          | Method                        | Benign nodular hyperplasia | Follicular adenoma | Follicular carcinoma | Hürthle cell carcinoma | Papillary carcinoma | Follicular variant of papillary | Anaplastic carcinoma |
|-----------------|-------------------------------|----------------------------|--------------------|----------------------|------------------------|---------------------|-------------------------------|---------------------|
| Kroll [3]       | RT-PCR                        | 0/10                       | 0/20               | 5/8 (63%)            | —                      | 0/10                | —                             | —                   |
| Martelli [14]   | RT-PCR                        | —                          | —                  | 0/5                 | —                      | 0/41                | —                             | 0/5                 |
| Zhu [38]        | RT-PCR                        | —                          | —                  | —                   | —                      | 0/46                | 0/30                          | —                   |
| Nikiforova [39] | RT-PCR and nested PCR         | 0/16                       | 2/25 (8%)          | 8/15 (53%)          | 0/12                   | 0/23                | 0/12                          | 0/2                 |
| Marques [36]    | RT-PCR and nested PCR         | 0/2                        | 2/16 (13%)         | 5/9 (56%)           | —                      | 0/9                 | 0/4                           | —                   |
| Aldred [29]     | RT-PCR                        | —                          | —                  | 2/19 (11%)          | —                      | —                   | —                             | —                   |
| Lacroix [40]    | RT-PCR                        | —                          | 1/16 (6%)          | 4/26 (15%)          | 0/4                    | —                   | —                             | 0/5                 |
| Hibi [41]       | RT-PCR                        | 0/12                       | 0/12               | 0/6                 | —                      | 0/12                | —                             | —                   |
| Marques [28]    | RT-PCR and FISH               | 0/28                       | 6/36 (17%)         | 6/24 (25%)          | —                      | 0/38                | —                             | —                   |
| Sahin [42]      | RT-PCR                        | —                          | 4/31 (13%)         | 31/54 (57%)         | 1/23 (4%)              | —                   | —                             | —                   |
| Nikiforova [43] | RT-PCR and FISH               | —                          | 1/23 (4%)          | 13/33 (36%)         | 0/19                   | —                   | —                             | —                   |
| Castro [44]     | RT-PCR and FISH               | —                          | —                  | —                   | —                      | 4/8 (50%)           | —                             | —                   |
| Cheung [37]     | RT-PCR                        | —                          | 6/11 (55%)         | 6/17 (35%)          | —                      | —                   | —                             | —                   |
| Foukakis [45]   | RT-PCR                        | —                          | 1/8 (13%)          | 5/25 (20%)          | —                      | —                   | —                             | —                   |
| Dwight [46]     | RT-PCR, FISH and Western      | —                          | 1/40 (3%)          | 10/34 (29%)         | —                      | —                   | —                             | 0/13                |
| Castro [47]     | RT-PCR and FISH               | —                          | 3/9 (33.3%)        | 10/22 (45.5%)       | —                      | 0/2                 | 9/24 (37.5%)                 | —                   |
| Giordano [48]   | RT-PCR                        | —                          | —                  | 7/13 (54%)          | —                      | —                   | —                             | —                   |
| **TOTAL**       |                               | 0/68                       | 27/247 (11%)       | 112/310 (36%)       | 1/58 (2%)              | 0/172               | 13/83 (16%)                  | 0/29                |

In one case of follicular variant of papillary thyroid cancer (FVP) [49] and intense PPARγ immunostaining was seen in three PPFP-negative FVP [50], perhaps arguing for an alternative mechanism of PPARγ overexpression in these tumors. Although Castro et al. [44, 47] found that 37–50% of FVP were positive for PPFP by RT-PCR and FISH, three other studies have found no such rearrangements [36, 38, 39]. It is, nevertheless, tempting to speculate whether those few cases of FVP that develop lung metastasis [51] or display an encapsulated growth pattern [52] might behave with a phenotype more reminiscent of a follicular carcinoma than papillary because of PPFP expression. Larger studies are needed to determine the frequency of expression of PPFP in this tumor variant, and to assess the possible coexpression of genes known to be associated with PTC, such as RAS and BRAF mutations and RET/PTC rearrangements.

4. PAX8/PPARγ AND PPARγ FUNCTION

To further investigate the function of PAX8/PPARγ−1, Kroll evaluated PPARγ response element (PPRE) activity in the presence of the fusion gene and wild-type PPARγ in a PPARγ-null osteosarcoma U2OS cell line [3]. In contrast to the wild-type PPARγ gene, the fusion gene was ineffective in stimulating ligand-induced gene expression. Furthermore, the coexpression of the fusion gene with wild-type PPARγ abrogated the PPARγ-mediated gene expression, in an apparently dominant negative fashion [3].
In vitro studies using an immortalized human thyroid cell line have shown accelerated growth in cells transiently transfected with PPFP compared to wild-type PPARγ or vector only [53]. Increased proliferation was confirmed with cell cycle transit studies, which showed a lower proportion of PPFP-transfected cells in the resting-phase (G0/G1) compared to vector and diminished rates of apoptosis in the PPFP-positive cells. Similar results were seen with stable transfection experiments, in which cells stably expressing PPFP demonstrated a growth advantage over vector-transformed cells. These data are consistent with the hypothesis that PPFP, acting as a dominant negative inhibitor of wild-type PPARγ, inhibits the normal tumor suppressor mechanism of PPARγ, and consequently acts as an oncogene. Furthermore, PPFP stable cell lines showed improved colony-formation on soft agar, a characteristic associated with malignant transformation [53].

Consistent with Kroll's results, cotransfection of PPFP and wild-type PPARγ in immortalized human thyroid cells led to a significant decline in PPARγ transactivation [53]. In these studies, GW9662, a potent PPARγ inhibitor, demonstrated a dose-dependent increase in cell growth of vector-transfected cells, but did not increase growth further in the PPFP-transfected cells. Similar effects were observed upon expression of a dominant negative PPARγ mutant in these cells. Loss of contact inhibition and anchorage dependence, which also correlate with malignant transformation, were also observed upon overexpression of PPFP. The studies of Powell et al. [53] provided the first direct evidence for the oncogenic potential of the PAX8/PPARγ fusion gene, confirming increased proliferation, decreased apoptosis, and a dominant negative effect of PPFP on wild-type PPARγ.

The influence of PPFP on PPRE-dependent transcription appears to be cell line-dependent. Au et al. [54] demonstrated that the fusion gene not only had a dominant negative effect on PPRE expression in HeLa cells, but also stimulated the expression of the PPRE-dependent promoter in a PPARγ ligand-dependent manner in FRTL-5 and Nthy-ori cells, immortalized rat and human thyroid cell lines, respectively. These differences might be related to differences in the ways these cells have been immortalized. Thus HeLa cells utilized the HPV E6 gene and Nthy-ori cells were immortalized with the SV40 large T antigen, whereas FRTL5 cells are a continuous line of functional, nontransformed rat thyroid cells that depend on thyroid-stimulating hormone (TSH) for sustained growth. Whatever the mechanism, the results of Au et al. [54] are in direct contradiction to Powell's findings, in which PPARγ agonists did not augment the PPFP response [53]. The reasons for this discrepancy are not known. Nevertheless, PPFP expression in FRTL-5 cells showed increased proliferation by 3H-thymidine incorporation and soft agar assays [54], findings that are fully consistent with Powell's data [53]. Although further study is clearly warranted to clarify the mechanism of PPFP action in the cell lines, the data indicate that PPFP can act as a dominant negative inhibitor as well as an independent ligand-responsive transcription factor in a promoter-dependent manner.

It is still not clear whether PPFP alone is sufficient to promote tumorigenesis, or whether additional genetic events are a prerequisite for this fusion gene to exhibit an oncogenic impact. One strong candidate, RAS gene mutations, which are seen in up to 50% of follicular tumors, rarely occur within the same tumor as PAX8/PPARγ rearrangements, suggesting that these putative oncogenes form two distinct pathways of carcinogenesis [43]. For each of these pathways, an additional step or series of steps may be required before the development of the full malignant phenotype.

5. PAX8/PPARγ AND PAX8 FUNCTION

Relatively few studies have assessed the impact of PAX8/PPARγ rearrangements on wild-type PAX8 function. Au et al. [54] and Espadinha et al. [55] evaluated the impact of PAX8/PPARγ on genes containing PAX8 response elements: sodium-iodine symporter (NIS), thyroid peroxidase (TPO), thyroid stimulating hormone receptor (TSHR), and thyroglobulin (Tg). Each of these promoters is regulated by PAX8, while the Tg promoter is regulated by both PAX8 and thyroid transcription factor-1 (TTF1), which exhibit a synergistic effect when both promoters are combined in vitro. In human thyroid cancer cell lines, PPFP expression resulted in a complex mixture of stimulatory and inhibitory effects on PAX8-responsive genes, including in PPARγ ligand-dependent and -independent effects. NIS gene expression was stimulated in response to PPFP expression alone in one study [54], although this apparently stimulatory effect required cotransfection of PPFP with wild-type PAX8 in another study [55]. TPO transcription was also increased by PPFP [54], while TSHr expression was inhibited [55]. Repression of the Tg promoter was also seen in response to PPFP [54], but again one study found that cotransfection with PPFP and PAX8 was necessary for this inhibitory effect to be seen [55]. However, in both studies, the fusion gene inhibited PAX8-mediated transcription of Tg in a dominant-negative fashion [54, 55], while the addition of ciglitazone did not reverse this dominant negative effect [54].

Consequently, the effects of the PAX8-PPARγ gene translocation on PAX8 function seem to be complex. TSHr and Tg expressions, both of which are associated with highly differentiated thyroid tissue, are downregulated by PPFP, though it is not clear whether the reduced expression of these genes truly alters cell differentiation status in vivo. In contrast, NIS and TPO expression are enhanced by the expression of PPFP, although once again the impact on cell function is not known. Whether any of these findings relates directly to the oncogenic actions of PPFP, and consequently the impact on the behavior and biology of human FTC, remains to be determined.

6. PAX8/PPARγ REARRANGEMENTS: BENCH TO BEDSIDE

On the basis of the data discussed above, PPFP appears to be important in the development of at least a subset of thyroid follicular neoplasms, and has, therefore, been proposed as
a possible oncogene in follicular thyroid carcinoma. The most obvious direct clinical utility of this discovery is the possibility that PPFP status could provide a presurgical test of malignancy within the troublesome group of biopsy specimens currently described as “suspicious for follicular neoplasm.” These lesions represent approximately 20% of all fine needle aspiration biopsies of thyroid nodules, and create a diagnostic challenge because the minority (10–15%) that prove ultimately to be malignant cannot currently be distinguished by cytological criteria from those that prove to be benign. Consequently, the recommendation for all such patients would be to undergo surgery [56], something that might be avoided with a preoperative test of sufficient accuracy. Unfortunately, the finding of a subset of PPFP-positive adenomas reduces the negative predictive value of a preoperative PPFP biopsy finding to 47.4%, while the presence of PPFP in a minority of FTC reduces the positive predictive value to 80.6% (Table 1).

RT-PCR, real-time RT-PCR, and FISH have all been used experimentally to detect translocations, though none is yet proven in a prospective, clinical setting [3, 36, 39, 42]. PCR, probably the technique most easily adapted to a rapid turnover, clinical setting, is concordant with PPARY immunohistochemistry in up to 80% of cases [36]. When the definition of “positive” PPFP is restricted to only strong, diffuse staining, immunohistochemistry concordance improves to 100% in some studies [7, 39], and it may be that RT-PCR techniques will actually prove superior to the immunohistochemistry “gold standard” for the detection of the fusion event (Algeciras-Schinnich, A. and Grebe, S.K.G., unpublished data). The possibility of false-positive immunostaining is real since normal thyroid tissue, chronic lymphocytic thyroiditis, or benign tissue adjacent to malignancies may show moderate to strong nuclear staining for PPARY expression. [39, 57], so the RT-PCR-based approach may prove to have a better negative predictive value. There are a number of possible explanations for this apparently “false-positive” staining, including alternate PAX8/PPARY breakpoints, 3p25 aneusomy, overexpression of wild-type PPARY, or rearrangements involving PPARY and a non-PAX8 partner [57]. Despite these challenges, Sahin et al. demonstrated that a reliable preoperative assay for PPFP might improve the accuracy of intraoperative frozen section by significantly reducing the false-negative rate of this technique, and therefore reducing the need for second (completion) surgeries for patients with follicular carcinoma who undergo primary thyroid lobectomy [42]. Immunohistochemistry formed the basis for this retrospective study, so clinical implementation would require confirmation with a more practical preoperative or intraoperative technique (most likely RT-PCR). In this archival tissue analysis, however, the sensitivity was improved from 85% with frozen section alone to 97% with the combination of frozen section and PPARY status. Several false-positive PPARY staining results led to a positive predictive value of only 72%, but the overall negative predictive value of frozen section plus immunostaining at this institution was 99%, meaning that five additional cases of carcinoma in this series of 39 cancers could have been identified intraoperatively, reducing the need for completion thyroidectomy to a single patient (3%).

Currently, there is no evidence that PPFP status predicts outcome in follicular thyroid cancer, with no correlation with proven predictive factors of gender, age, regional nodal spread, or tumor size [28, 39, 42]. The same is true for PPARY aneusomy or other PPARY rearrangements found in follicular cancers, which is not correlated with TNM stage [7]. However, patients with PPARY rearrangements may have a higher prevalence of previous nonthyroid cancers [7] and PPFP rearrangements may be associated with an increased incidence of multifocal capsular invasion or vascular invasion [39], although all of these findings remain in dispute [28, 42]. Larger and more comprehensive outcome analysis will be necessary to resolve these differences in the findings of multiple small studies.

7. **PPARY AGONIST THERAPY IN THYROID CANCER**

Follicular cell-derived thyroid cancers carry a generally good prognosis. Standard therapy involves near-total resection of the thyroid with adjuvant 131I radioablation of remnant thyroid tissue in most cases. A subset of tumors exhibits a more aggressive clinical course, and may show features of dedifferentiation, which has been associated with decreased expression of thyroid-specific genes such as Tg, TPO, NIS, and TSHR [15, 58]. These dedifferentiated thyroid cancers may consequently lose their ability to accumulate and concentrate radioiodine, making these tumors unresponsive to further 131I therapy. Traditionally, patients with iodine-insensitive tumors have had few therapeutic options and further basic and applied research is needed to identify suitable therapeutic targets for treatment of these patients; PPARY provides one such target.

Thiazolidinediones, including troglitazone, rosiglitazone, and pioglitazone, are PPARY agonists used in the treatment of type 2 diabetes. These and other PPARY agonists have been investigated in vitro in various cancer cell lines with evidence of growth inhibition and tumor cell apoptosis [18–23, 59]. Small clinical trials in liposarcoma and prostate cancer, which exhibit PPARY expression, have also been promising in these malignancies, which exhibit PPARY expression [60, 61]. Recent in vitro evaluations in thyroid cancer cell lines have hinted at a possible role for PPARY agonist therapy in redifferentiating neoplastic tissue, potentially enhancing the response to currently available therapies [62–67]. Expression of CD97, a marker of cell dedifferentiation, decreased in one follicular carcinoma cell line after therapy with troglitazone [16]. In the same experiment, expression of NIS, a gene associated with differentiating thyroid tissue, whose protein product is responsible for iodine concentration within thyroid cells, increased with agonist treatment compared to control in both a papillary and follicular carcinoma cell lines. Such an approach of “redifferentiation” might open up the possibility to restore radioactive iodine sensitivity in some tumors. Anaplastic cancer cell lines have been studied in similar experiments, and expressions of Tg, TSHR, NIS, and TPO were all increased after treatment with rosiglitazone [12].
These findings imply that PPARγ agonists may prove to be an effective therapy for improving response to 131I radiotherapy, even in patients without known PAX8/PPARγ rearrangements.

To date, three reports have been published assessing rosiglitazone therapy in patients with recurrent thyroid cancer as indicated by elevated Tg levels, but negative pretreatment whole body iodine scans (Tg-positive, scan-negative thyroid cancer). Phillips et al. [68] treated 2 follicular cancer and 3 papillary cancer patients with rosiglitazone 4 mg daily for one month and then 8 mg daily for three months. Whole body 131I scanning (WBS) using recombinant human TSH (rh-TSH) was negative for all 5 patients at the onset of the study. Basal Tg levels rose in 3 patients while the rhTSH-stimulated Tg increased in two of the 3 patients after rosiglitazone therapy. Posttreatment rhTSH-stimulated WBS was faintly positive in one patient. Elias and Lizotte [69] reported a single case of papillary thyroid cancer in which rosiglitazone caused a marked increase in 131I uptake on WBS. Following treatment with 250 mCi 131I, the WBS became negative, suggesting that the cancer had been effectively treated. Kekeb et al. [70] have reported the largest number of patients to date treated with a thiazolidinedione: 8 PTC, 1 FVP, and 1 FTC. These patients received rosiglitazone 4 mg daily for 7 days, then 8 mg daily for 49 days. Four patients (40%) had conversion from negative to positive WBS after rosiglitazone, suggesting a possible redifferentiation effect. At 6 months of followup, 2 patients had improved Tg levels (one follicular and one FVP patient), 3 had stable levels (all papillary cancer patients), and 5 patients had increased Tg levels compared to baseline. After 11 months of followup, 4 patients had a partial response to rosiglitazone, exhibiting decreased Tg levels or increased 131I uptake, 4 had stable disease, and 2 had progression of disease as indicated by increased Tg levels. In all cases, rosiglitazone was apparently well tolerated with no significant adverse events. Overall, 6 of 16 patients (5 papillary, 1 FVP) showed uptake on WBS after rosiglitazone therapy, indicating that a subset of patients may have experienced redifferentiation of their cancers. Whole body iodine scanning did not always correlate with Tg levels and caution should be exercised in interpreting Tg levels in these studies because an increase in Tg could indicate improved differentiation, rather than being a sign of increasing tumor mass. Only one patient in this study received additional 131I radiotherapy, although therapy was apparently successful, with a low Tg post-radiotherapy. Larger studies with longer followup are needed to see if thyroid cancers treated with PPARγ agonists show improved response to 131I radioablation or decreased mortality, the truly important clinical outcome.

Very little data is currently available on combination therapy with PPARγ and other chemotherapeutic agents. Aiello et al. [12] evaluated the in vitro response of rosiglitazone plus doxorubicin, a standard agent used in anaplastic thyroid cancer, in ATC cell lines. They found a markedly increased effect of doxorubicin in PPARγ-positive cell lines when combined with rosiglitazone, but no effect in a PPARγ-negative cell line. Copland et al. [71] combined paclitaxel with a novel PPARγ agonist, RS5444, in a variety of ATC cell lines. This combination demonstrated synergistic effects on inhibition of proliferation and stimulation of apoptosis in vitro. When athymic nude mice were implanted with the responsive ATC cell lines, tumor growth was inhibited by monotherapy with RS5444. No clinical studies or case reports have yet addressed combination therapy in humans with thyroid cancer, though a clinical trial is currently under development by our group.

8. CONCLUSION

Emerging genetic and molecular information acquired over the last 2 decades has begun to unravel the pathogenesis of thyroid cancer and in the future may open the door to potential novel therapies for patients with previously untreatable disease. Research focusing on PPARγ in a variety of cancer cell lines has implied a tumor suppressor function for wild-type PPARγ, while PPARγ downregulation or inhibition may be one factor in the development of at least some thyroid cancer types.

Chromosomal alterations of PPARγ, resulting in the expression of the fusion protein PPFP, may be an early event in the development or progression of follicular thyroid cancer and perhaps the follicular variant of papillary cancer. The detection of these alterations in FAs may support a stepwise adenoma to carcinoma sequence, or indicate the presence of “carcinoma in situ.” However, the PAX8/PPARγ rearrangement in itself may not be sufficient for the development of a malignant phenotype: additional genetic or epigenetic events may be required to enable the full phenotypic expression of follicular thyroid carcinoma.

Several lines of data suggest that PPFP, either through PPARγ inhibition, PAX8-dependent gene expression modulation, or both, leads to downstream effects, which are at least in part mediated by the NFκB pathway. These altered pathways stimulate cell proliferation and inhibit apoptosis, but there may be several other paths through which PPFP modulates the tumor phenotype, including alteration of cell differentiation status and expression of the sodium iodide transporter NIS, which may have an impact on the efficacy of our current therapeutic options.

PPARγ represents an attractive therapeutic target in a variety of thyroid cancers, including anaplastic, follicular, and papillary thyroid cancers. Although in vitro data is promising, early studies using PPARγ agonists to treat iodine-insensitive recurrent thyroid cancer are promising, but inconclusive so far. Larger studies with longer followup will be needed to clarify the potential for PPARγ agonists to act as “redifferentiation” agents. Nevertheless, the availability of a number of approved, orally administered, well-tolerated agents makes this group of drugs an attractive option for study.

ACKNOWLEDGMENTS

This research was supported by NIH Grant no. CA080117 (NLE), by an award from the American Thyroid Association (HVR), and by funds from the Mayo Foundation.
K. Ohta, T. Endo, and T. Onaya, "The mRNA levels of N. Hayashi, S. Nakamori, N. Hiraoka, et al., "Antitumor effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth," The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 11, pp. 3684–3691, 1997.

M. A. Herrmann, I. D. Hay, D. H. Bartelt Jr., et al., "Cyto genetic and molecular genetic studies of follicular and papillary thyroid cancers," The Journal of Clinical Investigation, vol. 88, no. 5, pp. 1596–1604, 1991.

R. B. Jenkins, I. D. Hay, J. F. Herath, et al., "Frequent occurrence of cyto genetic abnormalities in sporadic nonmedullary thyroid carcinoma," Cancer, vol. 66, no. 6, pp. 1213–1220, 1990.

C. A. French, E. K. Alexander, E. S. Cibas, et al., "Genetic and biological subgroups of low-stage follicular thyroid cancer," The American Journal of Pathology, vol. 162, no. 4, pp. 1053–1060, 2003.

J. Mark, C. Ekedahl, R. Dahlemfors, and B. Westermark, "Cytogenetical observations in five human anaplastic thyroid carcinomas," Hereditas, vol. 107, no. 2, pp. 163–174, 1987.

W.-O. Lui, S. Kytölä, L. Änfalk, C. Larsson, and L.-O. Farnebo, "Balanced translocation (3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma?" Cancer Genetics and Cytogenetics, vol. 119, no. 2, pp. 109–112, 2000.

G. Sozzi, M. Miozzo, T. C. Cariani, et al., "A t(2;3)(q12-p25;q34:34): another mechanism of tumorigenesis in follicular thyroid carcinoma?" Cancer Genetics and Cytogenetics, vol. 64, no. 1, pp. 38–41, 1992.

L. Roque, S. Castedo, A. Clode, and J. Soares, "Deletion of 3p25→pter in a primary follicular thyroid carcinoma and its metastases," Genes, Chromosomes & Cancer, vol. 8, no. 3, pp. 199–203, 1993.

A. Aiello, G. Pandini, F. Frasca, et al., "Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells," Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006.

N. Hayashi, S. Nakamori, N. Hiraoka, et al., "Antitumor effects of peroxisome proliferator-activated receptor gamma ligands on anaplastic thyroid carcinoma," International Journal of Oncology, vol. 24, no. 1, pp. 89–95, 2004.

M. L. Martelli, R. Iuliano, I. Le Pera, et al., "Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth," The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 10, pp. 4728–4735, 2002.

K. Ohta, T. Endo, and T. Onaya, "The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues," Biochemical & Biophysical Research Communications, vol. 174, no. 3, pp. 1148–1153, 1991.

J.-W. Park, R. Zarnegar, H. Kanauchi, et al., "Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines," Thyroid, vol. 15, no. 3, pp. 222–231, 2005.

Y. Chen, S.-M. Wang, J.-C. Wu, and S.-H. Huang, "Effects of PPARγ agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line," Journal of Cellular Biochemistry, vol. 98, no. 4, pp. 1021–1035, 2006.

S. Kitamura, Y. Miyazaki, Y. Shinomura, S. Kondo, S. Kanayama, and Y. Matsu zawa, "Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells," Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 75–80, 1999.

J. A. Keelan, T. A. Sato, K. W. Marvin, J. Land er, R. S. Gilmour, and M. D. Mitchell, "15-deoxy-Δ12,14-prostaglandin J2: a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells," Biochemical and Biophysical Research Communications, vol. 262, no. 3, pp. 579–585, 1999.

N. Takahashi, T. Okumura, W. Motomura, Y. Fujimoto, I. Kawabata, and Y. Kohgo, "Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells," FEBS Letters, vol. 455, no. 1–2, pp. 135–139, 1999.

P. Tontonoz, S. Singer, B. M. Forman, et al., "Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997.

T. Kubota, K. Koshizuka, E. A. Williamson, et al., "Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo," Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998.

E. Elsner, C. Müller, K. Koshizuka, et al., "Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998.

R. E. Weiss and S. Reffett, "Resistance to thyroid hormone," Reviews in Endocrine & Metabolic Disorders, vol. 1, no. 1–2, pp. 97–108, 2000.

H. Suzuki, M. C. Willingham, and S.-Y. Cheng, "Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis," Thyroid, vol. 12, no. 11, pp. 963–969, 2002.

H. Ying, H. Suzuki, H. Furumoto, et al., "Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma," Carcinogenesis, vol. 24, no. 9, pp. 1467–1479, 2003.

H. Ying, H. Suzuki, L. Zhao, M. C. Willingham, P. Meltzer, and S.-Y. Cheng, "Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis," Cancer Research, vol. 63, no. 17, pp. 5274–5280, 2003.

A. R. Marques, C. Espadinha, M. J. Frias, et al., "Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours," British Journal of Cancer, vol. 91, no. 4, pp. 732–738, 2004.

M. A. Aldred, C. Morrison, O. Gimm, et al., "Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas," Oncogene, vol. 22, no. 22, pp. 3412–3416, 2003.

T. E. Akaiyama, C. J. Nicol, and F. J. Gonzalez, "On par with PPARs," Trends in Genetics, vol. 17, no. 6, pp. 310–312, 2001.
[31] G. D. Gurnun, W. M. Smith, S. Driro, et al., “APC-dependent suppression of colon carcinogenesis by PPARγ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002.

[32] Y. Kato, H. Ying, L. Zhao, et al., “PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-xB signaling pathway,” Oncogene, vol. 25, no. 19, pp. 2736–2747, 2006.

[33] K. Setoguchi, Y. Misaki, Y. Terauchi, et al., “Peroxisome proliferator-activated receptor-γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis,” The Journal of Clinical Investigation, vol. 108, no. 11, pp. 1667–1675, 2001.

[34] M. L. C. Khoo, N. J. P. Beasley, S. Ezzat, J. L. Freeman, and S. L. Asa, “Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 8, pp. 3947–3952, 2002.

[35] J. Suh and A. B. Rabson, “NF-xB activation in human prostate cancer: important mediator or epiphenomenon?” Journal of Cellular Biochemistry, vol. 91, no. 1, pp. 100–117, 2004.

[36] A. R. Marques, C. Espadinha, A. L. Catarino, et al., “Expression of PAX8-PPARγ rearrangements in both follicular thyroid carcinomas and adenomas,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 8, pp. 3947–3952, 2002.

[37] L. Cheung, M. Messina, A. Gill, et al., “Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 354–357, 2003.

[38] Z. Zhu, M. Gandhi, M. N. Nikiforova, A. H. Fischer, and Y. E. Nikiforov, “Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations,” American Journal of Clinical Pathology, vol. 120, no. 1, pp. 71–77, 2003.

[39] M. N. Nikiforova, P. W. Biddinger, C. M. Caudill, T. G. Kroll, and Y. E. Nikiforov, “PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses,” American Journal of Surgical Pathology, vol. 26, no. 8, pp. 1016–1023, 2002.

[40] L. Lacroix, C. Mian, T. Barrier, et al., “PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues,” European Journal of Endocrinology, vol. 151, no. 3, pp. 367–374, 2004.

[41] Y. Hibi, T. Nagaya, F. Kambe, et al., “Is thyroid follicular cancer in Japanese caused by a specific t(2;3)(q13;p25) translocation generating Pax8-PPARγ fusion mRNA?” Endocrine Journal, vol. 51, no. 3, pp. 361–366, 2004.

[42] M. Sahin, B. L. Allard, M. Yates, et al., “PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 1, pp. 463–468, 2005.

[43] M. N. Nikiforova, R. A. Lynch, P. W. Biddinger, et al., “RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 5, pp. 2318–2326, 2003.

[44] P. Castro, L. Roque, J. Magalhães, and M. Sobrinho-Simões, “A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARγ translocation,” International Journal of Surgical Pathology, vol. 13, no. 3, pp. 235–238, 2005.

[45] T. Fournakis, A. Y. M. Au, G. Wallin, et al., “The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARγ fusion,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, pp. 1143–1149, 2006.

[46] T. Dwight, S. R. Thoppe, T. Fournakis, et al., “Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 9, pp. 4440–4445, 2003.

[47] P. Castro, A. P. Rebocho, R. J. Soares, et al., “PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 1, pp. 213–220, 2006.

[48] T. J. Giordano, A. Y. M. Au, R. Kuick, et al., “Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARγ translocation,” Clinical Cancer Research, vol. 12, no. 7, pp. 1983–1993, 2006.

[49] L. Roque, V. M. Nunes, C. Ribeiro, C. Martins, and J. Soares, “Karyotypic characterization of papillary thyroid carcinomas,” Cancer, vol. 92, no. 10, pp. 2529–2538, 2001.

[50] V. B. Wressmann, R. A. Góssesin, M. Hezel, et al., “Follicular variant of papillary thyroid carcinoma: genomic-wide appraisal of a controversial entity,” Genes, Chromosomes & Cancer, vol. 40, no. 4, pp. 355–364, 2004.

[51] M. L. Carcangiu, G. Zampi, and A. Pupi, “Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy,” Cancer, vol. 55, no. 4, pp. 805–828, 1985.

[52] P. Castro, E. Fonseca, J. Magalhães, and M. Sobrinho-Simões, “Follicular, papillary, and “hybrid” carcinomas of the thyroid,” Endocrine Pathology, vol. 13, no. 4, pp. 313–320, 2002.

[53] J. G. Powell, X. Wang, B. L. Allard, et al., “The PAX8/PPAR fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition,” Oncogene, vol. 23, no. 20, pp. 3634–3641, 2004.

[54] A. Y. M. Au, C. McBride, K. G. Wilhelm Jr., et al., “PAX8/peroxisome proliferator-activated receptor γ (PPARγ) disrupts normal PAX8 or PPARγ transcriptional function and stimulates follicular thyroid cell growth,” Endocrinology, vol. 147, no. 1, pp. 367–376, 2006.

[55] C. Espadinha, B. M. Cavaco, and V. Leite, “PAX8PPARγ stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line,” Thyroid, vol. 17, no. 6, pp. 497–509, 2007.

[56] D. S. Cooper, G. M. Doherty, B. R. Haugen, et al., “Management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 16, no. 2, pp. 109–142, 2006.

[57] K. S. Gustafson, V. A. LiVolsi, E. E. Furth, T. L. Pasha, M. E. Putt, and Z. W. Baloch, “Peroxisome proliferator-activated receptor γ expression in follicular-patterned thyroid lesions: caveats for the use of immunohistochemical studies,” American Journal of Clinical Pathology, vol. 120, no. 2, pp. 175–181, 2003.

[58] D. Fabbro, C. Di Loreto, C. A. Beltrami, A. Belfiore, R. Di Lauro, and G. Damante, “Expression of thyroid-specific transcription factors TFF-1 and PAX-8 in human thyroid neoplasms,” Cancer Research, vol. 54, no. 17, pp. 4744–4749, 1994.

[59] J. P. Klopper, W. R. Hays, V. Sharma, M. A. Baumbusch, J. M. Hershman, and B. R. Haugen, “Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression
predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment,” *Molecular Cancer Therapeutics*, vol. 3, no. 8, pp. 1011–1120, 2004.

[60] G. D. Demetri, C. D. M. Fletcher, E. Mueller, et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 7, pp. 3951–3956, 1999.

[61] E. Mueller, M. Smith, P. Sarraf, et al., “Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 20, pp. 10990–10995, 2000.

[62] F. Grünwald, C. Menzel, H. Bender, et al., “Redifferentiation therapy-induced radioiodine uptake in thyroid cancer,” *The Journal of Nuclear Medicine*, vol. 39, no. 11, pp. 1903–1906, 1998.

[63] F. Grünwald, E. Pakos, H. Bender, et al., “Redifferentiation therapy with retinoic acid in follicular thyroid cancer,” *The Journal of Nuclear Medicine*, vol. 39, no. 9, pp. 1555–1558, 1998.

[64] D. Simon, J. Koehrle, C. Reiners, et al., “Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma,” *World Journal of Surgery*, vol. 22, no. 6, pp. 569–574, 1998.

[65] Y. Zhang, S. Jia, Y. Liu, et al., “A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer,” *Nuclear Medicine Communications*, vol. 28, no. 4, pp. 251–255, 2007.

[66] D. Simon, C. Körber, M. Krausch, et al., “Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study,” *European Journal of Nuclear Medicine & Molecular Imaging*, vol. 29, no. 6, pp. 775–782, 2002.

[67] S. C. Short, A. Suovuori, G. Cook, G. Vivian, and C. Harmer, “A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer,” *Clinical Oncology*, vol. 16, no. 8, pp. 569–574, 2004.

[68] J.-C. Philips, C. Petite, J.-P. Willi, F. Buchegger, and C. A. Meier, “Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers,” *Nuclear Medicine Communications*, vol. 25, no. 12, pp. 1183–1186, 2004.

[69] A. N. Elias and P. Lizotte, “Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone,” *Clinical Nuclear Medicine*, vol. 31, no. 9, pp. 517–519, 2006.

[70] E. Kebebew, M. Peng, E. Reiff, et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” *Surgery*, vol. 140, no. 6, pp. 960–967, 2006.

[71] J. A. Copland, L. A. Marlow, S. Kurakata, et al., “Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” *Oncogene*, vol. 25, no. 16, pp. 2304–2317, 2006.